Get the Stockscreener App
2.11
0.94%
-0.02
In 8 Bio Inc stock is traded at $2.11, with a volume of 125.51K.
It is down -0.94% in the last 24 hours and up +1.93% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.13
Open:
$2.1
24h Volume:
125.51K
Relative Volume:
0.66
Market Cap:
$6.38M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.8133
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-13.52%
1M Performance:
+1.93%
6M Performance:
-72.50%
1Y Performance:
-91.73%
1-Day Range:
$2.07
$2.19
1-Week Range:
$2.07
$2.57
52-Week Range:
$2.05
$25.48
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.11 | 7.34M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
How many analysts rate bluebird bio Inc. as a “Buy”Low Risk Alerts Backed By Experts - jammulinksnews.com
INmune Bio to Present Q2 2025 Financial Results and Key Clinical-Stage Updates on August 7 - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
What are the latest earnings results for Climb Bio Inc.Advanced Screener Growth Plan For Fast Growth - jammulinksnews.com
How Palisade Bio Inc. stock performs during market volatilityPattern Recognition Based Market Move Prediction - Newser
What institutions are buying Korro Bio Inc. stock nowMarket Stability and Long-Term Growth Outlook - Newser
Is 2seventy bio Inc. forming a reversal patternFree Weekly Growth Stock Entry Point Alerts - Newser
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - jammulinksnews.com
Is 2seventy bio Inc. stock overvalued or undervaluedOverwhelming profit margins - jammulinksnews.com
What are analysts’ price targets for Korro Bio Inc. in the next 12 monthsBreakout portfolio performance - jammulinksnews.com
Moving Average Trends for 2seventy bio Inc. Stock: What They IndicateFree Professional Trading Signals - Newser
Layoff Tracker: Adicet’s Pipeline Optimization Push Claims 30% of Workforce - BioSpace
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
What drives INmune Bio Inc. stock priceSignificant capital appreciation - PrintWeekIndia
Adicet Bio Expands Autoimmune Disease Trial: First Systemic Sclerosis Patient Receives Novel T Cell Therapy - Stock Titan
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
What drives Adicet Bio Inc. stock priceFree Market Dynamics Reports - jammulinksnews.com
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
What analysts say about 2seventy bio Inc. stockExceptional return forecasts - Autocar Professional
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
What drives Mustang Bio Inc. stock priceMarket-leading growth rates - jammulinksnews.com
What analysts say about TELA Bio Inc. stockBreakout stock performance - Jammu Links News
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What drives Boundless Bio Inc. stock pricePowerful profit generation - jammulinksnews.com
Gossamer Bio Inc. Stock Analysis and ForecastMarket-leading capital gains - jammulinksnews.com
Why Climb Bio Inc. stock attracts strong analyst attentionEntry Level Low Risk Picks - Newser
Why Kronos Bio Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Passage Bio Announces Major 1-for-20 Reverse Split, Shares Reduced from 62M to 3M - Stock Titan
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - GlobeNewswire
Pre-market Movers: CLDI, BMGL, PROK, RXST... - RTTNews
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer - Yahoo Finance
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - Yahoo Finance
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
Breakthrough: New Alzheimer's Drug XPro Shows Promise in Key Patient Group, Zero ARIA Cases - Stock Titan
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SEC Filings Live FeedReal-Time 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical-Stage Immunology Company INmune Bio Secures $19M from Healthcare Investors at Market Price - Stock Titan
Major Alzheimer's Treatment Milestone: INmune Bio Reveals Phase 2 Trial Results Next Week - Stock Titan
BioCryst's ORLADEYO Pediatric HAE Review Extended by FDA to December 2025 | BCRX SEC FilingForm 8-K - Stock Titan
Breakthrough in Dementia Treatment: Gene Therapy Maintains 18-Month Efficacy with Lower Dose Success - Stock Titan
ANVS gains NYSE approval of compliance plan, delisting risk eased | ANVS SEC FilingForm 8-K - Stock Titan
Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Quantisnow
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - Yahoo Finance
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):